
2019-nCoV Spike Protein RBD (Delta, L452R, T478K, 319-535)
$1,036.00 - $2,762.00
All products have special prices for bulk purchase, please contact for more details if required.
Cat. No.: RMLIF-10 (for 10μg)
Cat. No.: RMLIF-50 (for 50μg)
Cat. No.: RMLIF-200 (for 200μg)
Species | Gene ID | Accession | EC | Source | Length | MW | Tag |
|
|
|
|
|
|
|
|
别名(Synonyms)
RBD domain of 2019-nCoV Spike Protein, 2019-nCoV Spike Protein S1 RBD, Spike Protein S1 Subunit RBD of 2019-nCoV, 2019-nCov RBD Protein, 2019-nCoV Spike RBD Protein, L452R and T478K Mutation, First identified in India (B.1.617.2).
产品简介(Background)
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. Spike Protein, the main surface antigen of the coronavirus, is a ∼180kD glycoprotein that crucial for viral fusion and entry into the host cells. It is a homotrimeric, consisting of two subunits, S1 and S2. In SARS-CoV-2, proteolytic cleavage of spike protein into S1 and S2 subunits is required for its activation. The first step of coronavirus infection of virus is the interaction of the spike protein to certain receptors on host cells. The S1 subunit is focused on attachment of the protein to the receptor while the S2 subunit is involved with membrane fusion. The receptor binding domain (RBD) locates in the C-terminal region of S1, and it binds to Angiotensin-Converting Enzyme 2 (ACE2) of host cells with high affinity and fast binding kinetic. Blocking the interaction between ACE2 and RBD inhibits the viral infection. RBD-specific antibodies have been shown to inhibit the attachment of RBD to ACE2-expressing cells, suggesting RBD as a potential target for vaccinations or therapy of SARS-CoV-2 infection. The attributes of Delta variants: Increased transmissibility; Potential reduction in neutralization by some EUA monoclonal antibody treatments; Potential reduction in neutralization by post-vaccination sera.
产品用途(Applications)
用于新型冠状病毒抑制剂的筛选、抗体制备、ELISA的标准蛋白或结构研究
外观(Physical appearance)
液体
活性(Biological activity) -
活力单位(Unit definition) -
浓度(Concentration)
≥0.1mg/ml
纯度(Purity)
≥ 95% by SDS-PAGE.
配方(Formulation)
PBS, pH7.4
使用方法(Recommended usage) -
氨基酸序列(Amino acid sequence)
RVQPTESIVR FPNITNLCPF GEVFNATRFA SVYAWNRKRI SNCVADYSVL YNSASFSTFK CYGVSPTKLN DLCFTNVYAD SFVIRGDEVR QIAPGQTGKI ADYNYKLPDD FTGCVIAWNS NNLDSKVGGN YRYLYRLFRK SNLKPFERDI STEIYQAGSK PCNGVEGFNC YFPLQSYGFQ PTNGVGYQPY RVVVLSFELL HAPATVCGPK KSTNLVKNhh hhhh
Only for research and not intended for treatment of humans or animals
Journals Using SBS Genetech Products Universities Using SBS Genetech Products
SBS Genetech is a long-term sponsor of Cold Spring Harbor Laboratory